Onyx Scientific has been selected by Cancer Research UK to manage several of its drug development projects. Onyx will support a portfolio of drug substance campaigns covering the development and manufacture of API, including process development, solid-state chemistry, analytical and GMP synthesis of API for use in Phase I trials.
 
Cancer Research UK initially selected Onyx for a GMP synthesis project in 2011. Onyx has since become one of its preferred providers for API development and GMP synthesis.
 
Dr. Nigel Westwood, drug supply manager at Cancer Research UK, said, “Over the last few years, the team at Onyx Scientific has worked proactively with us on several challenging synthetic chemistry projects and provided exceptional value for the money, which has led to us to select them for several new projects based on their competitive costs and ability to delivery on time.
 
“Having sufficient quantities of API available in a timely manner is critical for our drug development activities. It therefore makes sense for our organization to work even more closely with Onyx as a partner,” added Dr. Westwood.
 
Denise Bowser, commercial director at Onyx Scientific, said, “Our team has developed an excellent partnership with Cancer Research UK and so we are naturally delighted to be working with them on such a raft of important projects.”